The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis.
Abstract
Inflammatory bowel diseases are characterized by disabilities in gastrointestinal system and defects in mucosal immune system. Statins are 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor and are used to treat hypercholesterolemia in patients with coronary artery and atherosclerotic diseases. Recent studies have demonstrated that statins have immunomodulatory role by effecting different pathways in immune system. In this study, we investigated the effect of atorvastatin and its mechanism on systemic immune response in treatment of trinitrobenzene sulfonic acid (TNBS)-induced colitis mice. We observed that atorvastatin significantly suppressed the severity of TNBS-induced colitis in BALB/c mice. This was manifested in reduced rectal bleeding, decrease in colon length, reduction of histological damage, and improved survival. Concurrently, we investigated the immunomodulatory role of atorvastatin on systemic immune system. We investigated the proinflammatory (IL-1α, IL-6, TNF-α), Th1 (IFN-γ, IL-2), Th2 (IL-4, IL-5, IL-10), and Th17 (IL-17, IL-23) cytokine levels in serum samples of colitis and atorvastatin-administered mice. We discovered that administration of atorvastatin significantly down-regulates systemic TNF-α level and Th17 cytokine levels. Furthermore, atorvastatin treatment switches Th1 type T-cell response toward/to Th2 (IL-4, IL-10) type response.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Atorvastatin decreases Th17 responses in various models and in humans.
“Atorvastatin, among other statins, was also shown to decrease Th17 responses in various models and in humans (Aktunc et al., 2011; Li et al., 2011; Jameel et al., 2013; Lappegard et al., 2013).”
From Atorvastatin Reduces the Survival of Candida albicans-Infected BALB/c Mice (2015) · cites this paper as Aktunc et al., 2011
Cites
Interleukin-17 Family Members and Inflammation
Kolls, J. K., & Lindén, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.018 · Cited by 2,371 · see citing works
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,848 · see citing works
IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6
Yen, D., Cheung, J., Scheerens, H., Poulet, F. M., McClanahan, T. K., McKenzie, B. S., Kleinschek, M. A., Owyang, A. M., Mattson, J. D., Blumenschein, W. M., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci21404 · Cited by 1,532 · see citing works
Statins as a newly recognized type of immunomodulator.
Kwak, B., Mulhaupt, F., Myit, S., & Mach, F. (2000) · Nature Medicine · doi:10.1038/82219 · Cited by 1,383 · see citing works
Cai, Y., Zheng, H., Gong, W. J., Che, Y., & Jiang, B. (2011) · Hepatogastroenterology · doi:10.5754/hge11155 · Cited by 1,257 · see citing works
Rutgeerts, P. J., D’Haens, G., Targan, S. R., Vasiliauskas, E. A., Hanauer, S. B., Present, D. H., Mayer, L., van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,078 · see citing works
Weitz‐Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J. A., Bruns, C., Cottens, S., Takada, Y., & Hommel, U. (2001) · Nature Medicine · doi:10.1038/89058 · Cited by 1,041 · see citing works
Powrie, F. M., Carlino, J. A., Leach, M. W., Mauze, S., & Coffman, R. L. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2669 · Cited by 894 · see citing works
D’Haens, G., van Deventer, S. J. H., van Hogezand, R. A., Chalmers, D. M., Kothe, C., Baert, F., Braakman, T., Schaible, T. F., Geboes, K., & Rutgeerts, P. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70005-3 · Cited by 744 · see citing works
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfová, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.024 · Cited by 614 · see citing works
Cytokines in Inflammatory Bowel Disease
Rogler, G., & Andus, T. (1998) · World Journal of Surgery · doi:10.1007/s002689900401 · Cited by 483 · see citing works
Reuter, B. K., Asfaha, S., Buret, A. G., Sharkey, K. A., & Wallace, J. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119013 · Cited by 423 · see citing works
A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease
Plevy, S. E., Landers, C. J., Prehn, J., Carramanzana, N., Deem, R. L., Shealy, D. J., & Targan, S. R. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.12.6276 · Cited by 379 · see citing works
Biologic therapy of inflammatory bowel disease
Sandborn, W. J., & Targan, S. R. (2002) · Gastroenterology · doi:10.1053/gast.2002.33426 · Cited by 344 · see citing works
Evidence for continuous stimulation of interleukin-6 production in Crohn's disease
Groß, V., Andus, T., Caesar, I., Roth, M., & Schölmerich, J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90098-j · Cited by 293 · see citing works
The epidemiology and the pathogenesis of inflammatory bowel disease
Karlinger, K., Györke, T., Makó, E., Mester, Á. R., & Tarján, Z. (2000) · European Journal of Radiology · doi:10.1016/s0720-048x(00)00238-2 · Cited by 287 · see citing works
Pharmacology of competitive inhibitors of HMG-CoA reductase.
Corsini, A., Maggi, F., & Catapano, A. (1995) · Pharmacological Research · doi:10.1016/1043-6618(95)80042-5 · Cited by 282 · see citing works
Crohn's disease--a permeability disorder of the tight junction?
Hollander, D. (1988) · Gut · doi:10.1136/gut.29.12.1621 · Cited by 271 · see citing works
Immunopathogenesis of inflammatory bowel disease
Shih, D. Q., & Targan, S. R. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.14.390 · Cited by 197 · see citing works
Evolving paradigms in the pathogenesis of IBD
Mayer, L. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0138-3 · Cited by 175 · see citing works
Heo, Y., Joo, Y.-B., Oh, H., Park, M., Heo, Y., Cho, M., Kwok, S., Ju, J., Park, K.-S., Cho, S., et al. (2009) · Immunology Letters · doi:10.1016/j.imlet.2009.10.006 · Cited by 134 · see citing works
Inflammatory bowel disease: is it really just another break in the wall?: Figure 1
Weber, C. R., & Turner, J. R. (2006) · Gut · doi:10.1136/gut.2006.104182 · Cited by 132 · see citing works
Immunopathogenesis of inflammatory bowel disease: current concepts
Bamias, G., & Cominelli, F. (2007) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3281c55eb2 · Cited by 107 · see citing works
Environmental risk factors in inflammatory bowel disease.
Κoutroubakis, I. E., Manousos, O. N., Meuwissen, S. G. M., & Peña, A. S. (1996) · PubMed · Cited by 102 · see citing works
Lee, J. Y., Kim, J. S., Kim, J. M., Kim, N., Jung, H. C., & Song, I. S. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.10.013 · Cited by 98 · see citing works
Update on statin-mediated anti-inflammatory activities in atherosclerosis
Montecucco, F., & Mach, F. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0150-y · Cited by 89 · see citing works
Liu, W., Li, W., Gao, C., & Sun, N. (2005) · Journal of Autoimmunity · doi:10.1016/j.jaut.2005.06.005 · Cited by 69 · see citing works
Aharoni, R., Kayhan, B., Brenner, O. J., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103192 · Cited by 60 · see citing works
Self-citationStumpf, C., Petzi, S., Seybold, K., Wasmeier, G. H., Arnold, M. B., Raaz, D., Yılmaz, A., Daniel, W. G., & Garlichs, C. D. (2008) · Clinical Science · doi:10.1042/cs20080042 · Cited by 55 · see citing works
Atorvastatin Modulates Th1/Th2 Response in Patients With Chronic Heart Failure
Cheng, X. C., Ding, Y., Xia, C., Tang, T., Yu, X., Xie, J.-J., Liao, M., Yao, R., Chen, Y., Wang, M., et al. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.10.001 · Cited by 54 · see citing works
Pediatric Inflammatory Bowel Disease: Is It Different?
Levine, A. (2009) · Digestive Diseases · doi:10.1159/000228552 · Cited by 50 · see citing works
Immunotherapy of Crohn's Disease
Deventer, V. (2000) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2000.00657.x · Cited by 42 · see citing works
Ikeda, M., Takeshima, F., Isomoto, H., Shikuwa, S., Mizuta, Y., Ozono, Y., & Kohno, S. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-0102-0 · Cited by 39 · see citing works
Aharoni, R., Kayhan, B., & Arnon, R. (2005) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200502000-00003 · Cited by 32 · see citing works
Self-citationCirculating Cytokines Reflect Mucosal Inflammatory Status in Patients with Crohn’s Disease
Ljuca, F., Gegic, A., Salkic, N. N., et al. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1016-9 · Cited by 26 · see citing works
Kamm, C. P., Mattle, H. P., & SWABIMS Study Group (2009) · Trials · doi:10.1186/1745-6215-10-115 · Cited by 11 · see citing works
[The use of atorvastatin in patients with rheumatoid arthritis with hyperlipidemia].
Никитина, Н. М., & Ребров, А. П. (2009) · PubMed · Cited by 4 · see citing works
[Anti-inflammatory effect of HMG-CoA reductase inhibitors].
Kitamoto, S., & Egashira, K. (2004) · PubMed · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Jameel, A., Ooi, K. G.-J., Jeffs, N. R., Galatowicz, G., Lightman, S. L., & Calder, V. L. (2013) · International Journal of Inflammation · doi:10.1155/2013/434586 · Cited by 43 · see citing works
Atorvastatin Reduces the Survival of Candida albicans-Infected BALB/c Mice
Rahal, E. A., Constantin, W. N., Zeidan, N., & Abdelnoor, A. M. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01474 · Cited by 14 · see citing works
- Authors
- Aktunc, E., Kayhan, B., Arasli, M., Gun, B. D., & Barut, F.
- Affiliations
- Zonguldak Bülent Ecevit University (TR)
- ORCID
- Barut, Figen
- Venue
- Immunopharmacology and Immunotoxicology
- Publisher
- Informa UK Limited
- Published
- 2011-03-23
- Volume
- 33
- Issue
- 4
- Pages
- 667-675
- ISSN
- 0892-3973 (ISSN-L)
- 1532-2513
- OpenAlex
- W2014291574
- Cited by
- 44
- References
- 38
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 4 · 2018: 1 · 2017: 1 · 2016: 6 · 2015: 3 · 2014: 1 · 2013: 4 · 2012: 1
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Immunopharmacology and Immunotoxicology (publishedVersion)
- PubMed (publishedVersion)
- Zonguldak Bülent Ecevit University Institutional Repository (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- atorvastatin, statins, inflammatory bowel disease, TNBS-induced colitis, experimental colitis, cytokines, Th1/Th2 balance, Th17 cells, TNF-α, immunomodulation, IL-17, IL-23, IL-4, IL-10, interleukin-6, IL-1α, interferon-gamma, interleukin-2
- MeSH terms
- Atorvastatin, Acute Disease, Animals, Colitis, Disease Models, Animal, Heptanoic Acids, Humans, Immunologic Factors, Mice, Inbred BALB C, Pyrroles, Down-Regulation, Cytokines, Th1 Cells, Th2 Cells, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
